Diagnostic Utility of Tetra-NIRS in Conjunction With Urodynamic Studies
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this evaluation is to validate the previous clinical study results using the Tetra-NIRS as compared to the conventional UDS in the voiding procedure. The experiment will use a commercially available Tetra-NIRS device.
The hypothesis is that the commercially available Tetra-NIRS device, in the clinical environment, provides data to enhance the analysis using the standard urodynamics equipment (stand-alone Urodynamix procedure).
| Condition | Intervention | Phase |
|---|---|---|
|
Lower Urinary Tract Symptoms Overactive Bladder |
Device: TETRA - NIRS |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Diagnostic |
| Official Title: | The Purpose of This Experiment is to Validate the Previous Clinical Study Results Using the Tetra-NIRS as Compared to the Conventional UDS in the Voiding Procedure. This Evaluation Will Use a Commercially Available Tetra-NIRS Device. |
- The hypothesis is that the commercially available Tetra-NIRS device, in the clinical environment, provides data to enhance the analysis using the standard urodynamics equipment (stand-alone UDS). [ Time Frame: 1 Year ] [ Designated as safety issue: No ]
| Enrollment: | 154 |
| Study Start Date: | April 2009 |
| Study Completion Date: | February 2012 |
| Primary Completion Date: | February 2012 (Final data collection date for primary outcome measure) |
-
Device: TETRA - NIRS
This is a study of the commercially available Tetra-NIRS device to confirm the results collected using the commercially available Tetra-NIRS device. The study will evaluate male patients with lower urinary tract symptoms (LUTS). The study will also include and evaluate female subjects with over-active bladder (OAB).
The Tetra-NIRS unit uses near infrared light at 3 different wavelengths to measure changes in haemoglobin and cytochrome from the detrusor muscle from the human bladder wall. This process is similar to what is used for cerebral and muscle oxygenation monitoring (e.g., pulse oximetry). Previous clinical feasibility studies have identified the correlation between the changes in haemoglobin and cytochrome and the pressure values obtained during urodynamics procedures and uroflow procedures.
For this study the Tetra-NIRS results specifically will not be used by the urologist/nurse to guide in patient management and treatment decisions, but rather will only be used to collect measurements from the patient. The Tetra-NIRS sensor patch will be adhered to skin surface where their bladder is located.
For this reproducibility study a minimum of 30 male subjects with LUTS scheduled to undergo a urodynamics procedure are to be enrolled. Up to 20 female subjects with OAB will be enrolled. The investigators will attempt to equally enrol male subjects into each of the two categories including obstructed and non-obstructed groups (equivocal subjects will be determined by the investigator). Refer to Appendix A for additional information on sample size justification.
The investigators should seek to enroll a minimum of 10% of the subjects with a Body Mass Index (BMI) > 30, where BMI is calculated:
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
The selection of subjects enrolled for testing must meet the following criteria:
- Subjects must be 18 years of age or older.
- Subjects are patients of one of the institutions and are currently scheduled for UDS
- Male subjects must have LUTS
- Female subjects must have OAB
- Subjects must give their informed consent prior to enrolment.
Exclusion Criteria:
- The patient has an existing health condition which the investigators feel will not allow for safe or accurate measurements with the Tetra-NIRS device.
Contacts and Locations| United States, Tennessee | |
| Vanderbilt University | |
| Nashville, Tennessee, United States | |
| Canada, Ontario | |
| Sunnybrook Health Sciences Centre | |
| Toronto, Ontario, Canada | |
| United Kingdom | |
| King's College Hospital NHS Foundation Trust | |
| London, United Kingdom | |
| Principal Investigator: | Sender Herschorn, MD | Sunnybrook Health Sciences Centre |
More Information
No publications provided
| Responsible Party: | Laborie Medical Technologies Inc. |
| ClinicalTrials.gov Identifier: | NCT00871975 History of Changes |
| Obsolete Identifiers: | NCT00849225 |
| Other Study ID Numbers: | C001-C0015 TETRA-NIRS |
| Study First Received: | March 26, 2009 |
| Last Updated: | May 16, 2012 |
| Health Authority: | United States: Institutional Review Board Canada: Health Canada United Kingdom: Research Ethics Committee |
Keywords provided by Laborie Medical Technologies Inc.:
|
LUTS OAB |
Additional relevant MeSH terms:
|
Urinary Bladder, Overactive Urinary Bladder Diseases Urologic Diseases Urological Manifestations Signs and Symptoms Tetracycline Protein Synthesis Inhibitors |
Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Anti-Bacterial Agents Anti-Infective Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on May 22, 2013